Novel DREADD actuator for the first peripherally restricted DREADD system named the HCAD DREADD system. Water soluble. The HCAD system enables precise study of peripheral physiology without CNS interference.
Â
FCH-2296413 does not cross the BBB (unlike other DREADD ligands (e.g. CNO & DCZ)), so can selectively activate the novel, peripherally restricted HCAD Gi-DREADD. Few DREADD studies have been conducted in the PNS to date.
Â
FCH-2296413 has excellent drug-like properties, peripherally restricted pharmacokinetics and clean off-target profiles. The HCAD system also selectively reduces pain in mice by targeting peripheral tissues of DRG (dorsal root ganglion). Active in-vivo. FCH-2296413 is a racemic mixture which includes the racemates AR2599088 ('088) and AR259089 ('089).
Solubility & Handling
Solubility overview
Soluble in water (100 mM)
Storage instructions
-20°C
Storage of solutions
Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions
Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use
Understanding purity and quality - a guide for life scientists
